Skip to main content
Fig. 7 | Clinical Epigenetics

Fig. 7

From: Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription

Fig. 7

SMYD3 enhances HMGA2 transcription by binding to the HMGA2 promoter and increasing H3K4me3 modification. A, B The mRNA and protein levels of HMGA2 in CAL-27 and UM-SCC-1 cells transfected with SMYD3 siRNA. C, D The mRNA and protein levels of HMGA2 in CAL-27 and UM-SCC-1 cells transfected with SMYD3 plasmid. E, F The mRNA and protein levels of HMGA2 in CAL-27 and UM-SCC-1 cells following BCI-121 treatment. G HMGA2 expression was significantly decreased in the shSMYD3 group than in the shNC group of xenografts (n = 6/group). Scale bars: 50 μm. H HMGA2 expression was significantly reduced in the BCI-121 treatment group than in the vehicle group of xenografts (n = 6/group). Scale bars: 50 μm. I HMGA2 expression was significantly reduced in the BCI-121 treatment group than in the vehicle group of 4NQO-induced OSCC tissues (n = 7/group). Scale bars: 50 μm. J The SMYD3 potential binding sites in human HMGA2 promoter. K, L ChIP assays were performed to identify occupancy of the HMGA2 promoter in OSCC cells using SMYD3 antibodies. M Enrichment of H3K4me3 on the Site2 fragment of HMGA2 promoter. N–P Transcriptional activity of SMYD3 was assessed using a luciferase reporter system in OSCC cells. Ns, not significant, *P < 0.05, **P ≤ 0.01, and ***P ≤ 0.001

Back to article page